One of the big, unanswered questions that is obsessing payers and biopharma execs alike is just how much a new generation of biosimilars can save the healthcare industry through lower prices. So Rand set out to model the marketing of these follow-ons, which are gradually gaining steam in the late-stage pipeline. Rand's number: $44.2 billion over 10 years. Rand based its estimate on an examination of more than 100 biologics on the market, including all the blockbusters. While consumers are expected to net some of the savings, the real winners may be physicians and hospitals, which administer these drugs. Release